Solid Biosciences Added to Russell 3000 Index

Solid Biosciences Inc., a specialized life sciences company, has announced its addition to the Russell 3000® Index as part of the annual reconstitution process. This inclusion becomes effective at the opening of US equity markets on July 1, 2024. The Russell US Indexes annual reconstitution identifies the top 4,000 largest US stocks based on total market capitalization as of April 30th. Being part of the Russell 3000® Index ensures automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index and corresponding growth and value style indexes. FTSE Russell determines index membership primarily through objective market-cap rankings and style attributes.

Bo Cumbo, President and CEO of Solid Biosciences, highlighted the significance of this development, stating, "Our inclusion in the Russell 3000 Index reflects our significant progress as we continue to execute across our pipeline initiatives. Joining this prestigious index is an important milestone for Solid as it brings our Company enhanced exposure and broader visibility within the financial community."

Russell indexes play a vital role for investment managers and institutional investors, serving as benchmarks for index funds and active investment strategies. As of December 2023, approximately $10.5 trillion in assets were benchmarked against the Russell US indexes, managed by FTSE Russell, a global index provider.

Solid Biosciences is dedicated to advancing precision genetic medicines for neuromuscular and cardiac diseases. The company’s portfolio includes gene therapy candidates such as SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, AVB-401 for BAG3-mediated dilated cardiomyopathy, and other assets targeting fatal cardiac diseases. The company leverages expertise in science, technology, disease management, and patient care to develop its diverse pipeline. Founded by individuals directly impacted by such diseases, Solid Biosciences aims to enhance the daily lives of patients suffering from these debilitating conditions.

FTSE Russell, a leading provider of benchmarking, analytics, and data solutions, equips investors with detailed market insights relevant to their investment processes. The broad range of reliable indexes they offer helps measure and benchmark markets across various asset classes, styles, and strategies. FTSE Russell indexes are extensively used by institutional and retail investors globally, with over 30 years of experience in providing benchmarks for investment performance and creating ETFs, structured products, and index-based derivatives. The organization is committed to high industry standards in index design and governance, using transparent rules-based methodologies informed by independent committees. FTSE Russell fully adheres to the IOSCO Principles, with its compliance statement receiving independent assurance.

Solid Biosciences’ addition to the Russell 3000® Index marks a significant achievement, potentially enhancing its visibility and credibility within the financial community. This milestone underscores the company's progress in developing innovative genetic therapies and its commitment to improving the lives of patients with rare neuromuscular and cardiac diseases.